{"resourceType":"ValueSet","id":"detectedissue-category","meta":{"lastUpdated":"2015-10-24T07:41:03.495+11:00","profile":["http://hl7.org/fhir/StructureDefinition/valueset-shareable-definition"]},"extension":[{"url":"http://hl7.org/fhir/StructureDefinition/valueset-oid","valueUri":"urn:oid:2.16.840.1.113883.4.642.2.103"}],"url":"http://hl7.org/fhir/ValueSet/detectedissue-category","version":"1.0.2","name":"Detected Issue Category","status":"draft","experimental":true,"publisher":"FHIR Project team","contact":[{"telecom":[{"system":"other","value":"http://hl7.org/fhir"}]}],"date":"2015-10-24T07:41:03+11:00","description":"Kinds of issues or contraindications, such as \u0027drug-drug interaction\u0027, \u0027duplicate therapy\u0027, etc.","compose":{"include":[{"system":"http://hl7.org/fhir/v3/ActCode","filter":[{"property":"concept","op":"is-a","value":"_AdministrationDetectedIssueCode"}]},{"system":"http://hl7.org/fhir/v3/ActCode","filter":[{"property":"concept","op":"is-a","value":"_SupplyDetectedIssueCode"}]}]}}